Novo Nordisk's Wegovy Gains US Approval for MASH and Liver Disease
TL;DR Summary
Novo Nordisk's obesity drug Wegovy has received accelerated FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), a liver disease linked to obesity, after showing positive results in Phase 3 trials that improved liver fibrosis and symptoms.
- Novo Nordisk’s obesity drug Wegovy cleared to treat MASH statnews.com
- Novo Nordisk’s Wegovy Gets US Approval for Liver Disease Bloomberg.com
- Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis PR Newswire
- Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH Yahoo Finance
- Novo Nordisk's Wegovy gets accelerated US approval for liver disease MASH Reuters
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 1 min read
Condensed
80%
178 → 36 words
Want the full story? Read the original article
Read on statnews.com